807 related articles for article (PubMed ID: 15126373)
61. Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters.
Hoque MT; Kis O; De Rosa MF; Bendayan R
Antimicrob Agents Chemother; 2015 May; 59(5):2572-82. PubMed ID: 25691630
[TBL] [Abstract][Full Text] [Related]
62. Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
Bakhsheshian J; Wei BR; Chang KE; Shukla S; Ambudkar SV; Simpson RM; Gottesman MM; Hall MD
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20801-6. PubMed ID: 24297888
[TBL] [Abstract][Full Text] [Related]
63. ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.
Zhang P; de Gooijer MC; Buil LC; Beijnen JH; Li G; van Tellingen O
Int J Cancer; 2015 Oct; 137(8):2007-18. PubMed ID: 25868794
[TBL] [Abstract][Full Text] [Related]
64. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
[TBL] [Abstract][Full Text] [Related]
65. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
de Vries NA; Buckle T; Zhao J; Beijnen JH; Schellens JH; van Tellingen O
Invest New Drugs; 2012 Apr; 30(2):443-9. PubMed ID: 20963470
[TBL] [Abstract][Full Text] [Related]
66. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
[TBL] [Abstract][Full Text] [Related]
67. P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution.
Shaik N; Giri N; Pan G; Elmquist WF
Drug Metab Dispos; 2007 Nov; 35(11):2076-85. PubMed ID: 17709369
[TBL] [Abstract][Full Text] [Related]
68. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier.
Ose A; Kusuhara H; Yamatsugu K; Kanai M; Shibasaki M; Fujita T; Yamamoto A; Sugiyama Y
Drug Metab Dispos; 2008 Feb; 36(2):427-34. PubMed ID: 18039806
[TBL] [Abstract][Full Text] [Related]
69. Expression and function of multidrug resistance transporters at the blood-brain barriers.
Scherrmann JM
Expert Opin Drug Metab Toxicol; 2005 Aug; 1(2):233-46. PubMed ID: 16922639
[TBL] [Abstract][Full Text] [Related]
70. Involvement of multidrug resistance associated protein 1 (Mrp1) in the efflux transport of 17beta estradiol-D-17beta-glucuronide (E217betaG) across the blood-brain barrier.
Sugiyama D; Kusuhara H; Lee YJ; Sugiyama Y
Pharm Res; 2003 Sep; 20(9):1394-400. PubMed ID: 14567633
[TBL] [Abstract][Full Text] [Related]
71. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
[TBL] [Abstract][Full Text] [Related]
72. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
Shen H; Lee FY; Gan J
J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
[TBL] [Abstract][Full Text] [Related]
73. In vivo saturation of the transport of vinblastine and colchicine by P-glycoprotein at the rat blood-brain barrier.
Cisternino S; Rousselle C; Debray M; Scherrmann JM
Pharm Res; 2003 Oct; 20(10):1607-11. PubMed ID: 14620515
[TBL] [Abstract][Full Text] [Related]
74. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
Zaher H; Khan AA; Palandra J; Brayman TG; Yu L; Ware JA
Mol Pharm; 2006; 3(1):55-61. PubMed ID: 16686369
[TBL] [Abstract][Full Text] [Related]
75. Resolution of P-glycoprotein and non-P-glycoprotein effects on drug permeability using intestinal tissues from mdr1a (-/-) mice.
Stephens RH; O'Neill CA; Bennett J; Humphrey M; Henry B; Rowland M; Warhurst G
Br J Pharmacol; 2002 Apr; 135(8):2038-46. PubMed ID: 11959808
[TBL] [Abstract][Full Text] [Related]
76. A revised role for P-glycoprotein in the brain distribution of dexamethasone, cortisol, and corticosterone in wild-type and ABCB1A/B-deficient mice.
Mason BL; Pariante CM; Thomas SA
Endocrinology; 2008 Oct; 149(10):5244-53. PubMed ID: 18556350
[TBL] [Abstract][Full Text] [Related]
77. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
[TBL] [Abstract][Full Text] [Related]
78. Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain.
Oberoi RK; Mittapalli RK; Elmquist WF
J Pharmacol Exp Ther; 2013 Dec; 347(3):755-64. PubMed ID: 24113148
[TBL] [Abstract][Full Text] [Related]
79. ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
Lin F; de Gooijer MC; Roig EM; Buil LC; Christner SM; Beumer JH; Würdinger T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2014 May; 20(10):2703-13. PubMed ID: 24647572
[TBL] [Abstract][Full Text] [Related]
80. A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation.
Megard I; Garrigues A; Orlowski S; Jorajuria S; Clayette P; Ezan E; Mabondzo A
Brain Res; 2002 Feb; 927(2):153-67. PubMed ID: 11821009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]